MX2023002648A - Mutante de il-2 y aplicacion de este. - Google Patents
Mutante de il-2 y aplicacion de este.Info
- Publication number
- MX2023002648A MX2023002648A MX2023002648A MX2023002648A MX2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A
- Authority
- MX
- Mexico
- Prior art keywords
- mutant
- fusion protein
- compared
- application
- increases
- Prior art date
Links
- 101150083678 IL2 gene Proteins 0.000 title 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 7
- 108010002350 Interleukin-2 Proteins 0.000 abstract 7
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000027455 binding Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación describe mutantes de IL-2 y usos de estos. Más específicamente, la divulgación proporciona mutantes de IL-2 y proteínas de fusión correspondientes, conjugados, fragmentos de ácido nucleico, vectores, células hospedadoras, métodos para preparar los mutantes o proteínas de fusión, mutantes de IL-2 o proteínas de fusión que se preparan de acuerdo con los métodos, composiciones farmacéuticas, usos farmacéuticos, métodos para tratar enfermedades y métodos para estimular preferentemente los linfocitos T reguladores. En comparación con la IL-2 no modificada, los mutantes de IL-2 de la presente divulgación tienen valores de Tm más altos y una estabilidad mejorada; como alternativa, los mutantes de IL-2 de la presente divulgación tienen un mayor rendimiento o una actividad de unión modificada a los complejos IL-2Rß? en comparación con la IL-2 no modificada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010918842 | 2020-09-04 | ||
| CN202110932286 | 2021-08-13 | ||
| PCT/CN2021/116463 WO2022048640A1 (zh) | 2020-09-04 | 2021-09-03 | Il-2突变体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002648A true MX2023002648A (es) | 2023-04-05 |
Family
ID=80490673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002648A MX2023002648A (es) | 2020-09-04 | 2021-09-03 | Mutante de il-2 y aplicacion de este. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230265148A1 (es) |
| EP (1) | EP4209503A1 (es) |
| JP (1) | JP2023540761A (es) |
| KR (1) | KR20230061490A (es) |
| CN (1) | CN116323653A (es) |
| AU (1) | AU2021338393A1 (es) |
| BR (1) | BR112023004040A2 (es) |
| CA (1) | CA3191260A1 (es) |
| CL (1) | CL2023000631A1 (es) |
| IL (1) | IL301027A (es) |
| MX (1) | MX2023002648A (es) |
| PE (1) | PE20240123A1 (es) |
| TW (1) | TW202214677A (es) |
| WO (1) | WO2022048640A1 (es) |
| ZA (1) | ZA202304098B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023165553A1 (zh) * | 2022-03-03 | 2023-09-07 | 海南先声药业有限公司 | IL2突变体-抗体Fc嵌段融合蛋白的药物组合物及其应用 |
| WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| WO2023241653A1 (zh) * | 2022-06-17 | 2023-12-21 | 舒泰神（北京）生物制药股份有限公司 | 白介素-2(il-2)突变体及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23734A1 (es) * | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
-
2021
- 2021-09-03 AU AU2021338393A patent/AU2021338393A1/en active Pending
- 2021-09-03 IL IL301027A patent/IL301027A/en unknown
- 2021-09-03 KR KR1020237011285A patent/KR20230061490A/ko unknown
- 2021-09-03 US US18/024,151 patent/US20230265148A1/en active Pending
- 2021-09-03 TW TW110132852A patent/TW202214677A/zh unknown
- 2021-09-03 CA CA3191260A patent/CA3191260A1/en active Pending
- 2021-09-03 MX MX2023002648A patent/MX2023002648A/es unknown
- 2021-09-03 BR BR112023004040A patent/BR112023004040A2/pt unknown
- 2021-09-03 JP JP2023515158A patent/JP2023540761A/ja active Pending
- 2021-09-03 WO PCT/CN2021/116463 patent/WO2022048640A1/zh active Application Filing
- 2021-09-03 EP EP21863702.3A patent/EP4209503A1/en active Pending
- 2021-09-03 CN CN202180054574.5A patent/CN116323653A/zh active Pending
- 2021-09-03 PE PE2023000835A patent/PE20240123A1/es unknown
-
2023
- 2023-03-03 CL CL2023000631A patent/CL2023000631A1/es unknown
- 2023-04-03 ZA ZA2023/04098A patent/ZA202304098B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301027A (en) | 2023-05-01 |
| CL2023000631A1 (es) | 2023-10-13 |
| US20230265148A1 (en) | 2023-08-24 |
| PE20240123A1 (es) | 2024-01-22 |
| EP4209503A1 (en) | 2023-07-12 |
| AU2021338393A1 (en) | 2023-05-11 |
| TW202214677A (zh) | 2022-04-16 |
| JP2023540761A (ja) | 2023-09-26 |
| CA3191260A1 (en) | 2022-03-10 |
| BR112023004040A2 (pt) | 2023-04-04 |
| KR20230061490A (ko) | 2023-05-08 |
| ZA202304098B (en) | 2023-09-27 |
| CN116323653A (zh) | 2023-06-23 |
| WO2022048640A1 (zh) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002648A (es) | Mutante de il-2 y aplicacion de este. | |
| US20180271891A1 (en) | Selective treatment of prmt5 dependent cancer | |
| JP2021176866A (ja) | 共通ネオ抗原 | |
| CN107949641A (zh) | 用于基因组编辑的crispr/cas9复合物 | |
| EP3352782B1 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
| UA104890C2 (uk) | Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivo | |
| WO2005119251A3 (en) | Novel means and methods for the treatment of hearing loss and phantom hearing | |
| Hong et al. | Effect of sodium butyrate on the assembly, charge variants, and galactosylation of antibody produced in recombinant Chinese hamster ovary cells | |
| BR112022008744A2 (pt) | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| NO20055209D0 (no) | Peptabody for cancerbehandling | |
| JP7026906B2 (ja) | 転写調節融合ポリペプチド | |
| WO2012075173A3 (en) | Compositions and method for deimmunization of proteins | |
| WO2022089605A1 (en) | Modified red blood cells and uses thereof for delivering agents | |
| WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
| MX2020012499A (es) | Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh. | |
| CA3010598A1 (en) | Modulation of afucosylated species in a monoclonal antibody composition | |
| BR112021019570A2 (pt) | Proteína de fusão, imunoconjugado, ácido nucleico isolado, vetor, célula, composição, uso dos mesmos para tratar um tumor, bem como métodos para preparar a proteína de fusão, para bloquear a interação entre a proteína pd-l1 e pd-1 e entre cd47 e sirp-alfa e para inibir o crescimento e/ou proliferação de tumores ou células tumorais | |
| US20190048070A1 (en) | Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition | |
| Reinhart et al. | Differential gene expression of a feed-spiked super-producing CHO cell line | |
| WO2021133959A3 (en) | Compositions and methods for gamma delta tcr reprogramming using fusion proteins | |
| Godfrey et al. | Polysome profiling of mAb producing CHO cell lines links translational control of cell proliferation and recombinant mRNA loading onto ribosomes with global and recombinant protein synthesis | |
| Meunier et al. | Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation | |
| CN116802278A (zh) | 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤 | |
| KR20220103943A (ko) | 일차 인간 면역 세포에서 친전자체-시스테인 상호작용의 활성-가이드 맵 | |
| CN114457110A (zh) | 一种敲除fut8基因的方法 |